Mefenamic Acid Mercury Pharmaceuticals (Mefenamic Acid)

Mefenamic acid works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which blocks the conversion of arachidonic acid into prostaglandins. The resulting decrease in prostaglandin synthesis reduces peripheral sensitisation of pain receptors and dampens the inflammatory cascade, providing analgesic and anti‑inflammatory effects.

The appropriate dose of mefenamic acid is determined by the prescribing clinician based on the patient’s condition, age, weight, and renal or hepatic function. Typical adult regimens range from 250 mg to 500 mg taken two to three times daily, but exact dosing and treatment duration must follow the prescriber’s instructions.

The safety of mefenamic acid in pregnancy has not been established, and it is generally avoided, especially in the third trimester, due to potential fetal risks. Breastfeeding mothers should also use caution, as the drug can be excreted in milk; consultation with a healthcare professional is essential before use.

To place an order, visit the product page on gnhindia.com, enter the required quantity, and submit the inquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Compared with other NSAIDs, mefenamic acid belongs to the fenamate class and has a relatively rapid onset of analgesia. It may be preferred for dysmenorrhea due to its efficacy in uterine pain, but it shares similar gastrointestinal and renal risk profiles with other non‑selective NSAIDs, requiring comparable caution.

Mefenamic Acid Mercury Pharmaceuticals should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in their original container, protect them from moisture and direct sunlight, and ensure they are out of reach of children. Do not refrigerate or freeze the product.

The medication is supplied as oral tablets and should be taken with a full glass of water, preferably with food or milk to lessen gastrointestinal irritation. Swallow the tablet whole; do not crush or chew unless specifically directed by a healthcare professional.

The most serious risks include gastrointestinal bleeding or ulceration, severe renal impairment, hepatotoxicity, and life‑threatening hypersensitivity reactions such as anaphylaxis or Stevens‑Johnson syndrome. Patients should be monitored for signs of bleeding, kidney or liver dysfunction, and any allergic manifestations, and therapy should be stopped immediately if serious events occur.

Individuals with known hypersensitivity to mefenamic acid or other fenamates, those with active peptic ulcer disease, severe renal or hepatic impairment, and patients in the third trimester of pregnancy should avoid this medication. It is also contraindicated in patients taking anticoagulants combined with other NSAIDs due to heightened bleeding risk.